Is low fecal elastase a marker of exocrine pancreatic insufficiency and linked to fat/protein malabsorption and fat‑soluble vitamin deficiencies?

Fecal elastase-1 (FE-1) is a human-specific protease enzyme that remains stable during its passage through the digestive tract. Because its concentration in stool correlates with the secretory output of the pancreas, it has become a primary non-invasive biomarker used in clinical practice to assess pancreatic function.

Clinical evidence for pancreatic insufficiency

Low fecal elastase is an established diagnostic marker for exocrine pancreatic insufficiency (EPI). Clinical guidelines, including the United European Gastroenterology (UEG) HaPanEU guidelines, recommend FE-1 as a first-line diagnostic tool.

• Diagnostic Thresholds: A level above 200 μg/g is considered normal. Levels between 100–200 μg/g indicate mild-to-moderate EPI, while levels below 100 μg/g are strongly associated with severe disease.
• Accuracy: Meta-analyses report a high pooled sensitivity (0.94–0.96) for detecting moderate-to-severe EPI. However, sensitivity is notably lower in mild cases (as low as 6.25% in some cohorts), and false positives can occur in patients with watery diarrhea due to sample dilution.

Impact on macronutrient digestion

Low FE-1 reflects a global reduction in acinar cell secretion, which includes essential lipases (for fats) and proteases (for proteins).

• Fat Malabsorption: There is a robust correlation between low FE-1 and a reduced coefficient of fat absorption (CFA). In conditions like chronic pancreatitis, low FE-1 levels frequently predict steatorrhea (excess fat in stool), with prevalence rates reaching 48% or higher in affected populations.
• Protein Malabsorption: While less frequently quantified through direct fecal nitrogen testing in modern literature, low FE-1 is mechanistically linked to impaired protein breakdown. Severe cases are associated with broader malnutrition and hypoproteinemia.

Mechanistic link to vitamin deficiencies

Because the absorption of fat-soluble vitamins (A, D, E, and K) depends on pancreatic lipase for micelle formation, low FE-1 is a strong predictor of micronutrient deficiencies.

• Vitamin D: This is the most common deficiency, occurring in 22% to 62.5% of patients with low FE-1 or confirmed EPI.
• Vitamins A and E: Deficiencies are significant, with reported rates as high as 35.2% for Vitamin A and 17–38% for Vitamin E in chronic pancreatitis and cystic fibrosis populations.
• Vitamin K: While less frequently quantified, deficiency is clinically evidenced by cases of coagulopathy that resolve with pancreatic enzyme replacement therapy (PERT).

Bottom line

Low fecal elastase (<200 μg/g) is a scientifically validated marker for exocrine pancreatic insufficiency, directly leading to the malabsorption of fats and proteins and secondary deficiencies in vitamins A, D, E, and K. Clinical management typically requires screening for these micronutrient deficiencies and implementing enzyme replacement therapy.